BIOBOT Surgical
Singapore, Singapore· Est.
Robotic transperineal platform for precision prostate biopsy and ablation.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Robotic transperineal platform for precision prostate biopsy and ablation.
Oncology
Technology Platform
Robotic transperineal platform that fuses pre‑operative MRI with live ultrasound for sub‑millimeter needle placement in prostate biopsy and ablation.
Opportunities
Geographic expansion into high‑growth markets and extension of the robotic platform to additional soft‑tissue ablation indications beyond prostate cancer.
Risk Factors
Regulatory and reimbursement hurdles in new territories, competition from established imaging and robotic biopsy systems, and reliance on continued clinical adoption.
Competitive Landscape
Competes with transrectal biopsy kits (e.g., Hologic, Philips) and emerging robotic platforms (e.g., Medtronic, KOELIS), but differentiates through sub‑millimeter robotic accuracy, MRI‑ultrasound fusion, and a transperineal approach that reduces infection risk.